Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmaceutical compounding of aflibercept in prefilled syringes does not affect structural integrity, stability or VEGF and Fc binding properties
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-26
DOI
10.1038/s41598-018-20525-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network
- (2016) Carl W. Baker et al. CURRENT OPINION IN OPHTHALMOLOGY
- Ranibizumab or Bevacizumab for Neovascular Age-Related Macular Degeneration According to the Lucentis Compared to Avastin Study Treat-and-Extend Protocol
- (2016) Karina Berg et al. OPHTHALMOLOGY
- Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema
- (2016) John A. Wells et al. OPHTHALMOLOGY
- INTRAVITREAL INJECTIONS OF ZIV-AFLIBERCEPT FOR DIABETIC MACULAR EDEMA
- (2016) Gabriel Costa de Andrade et al. RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Ziv-aflibercept in macular disease
- (2015) Ahmad M Mansour et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Effect of Individual Fc Methionine Oxidation on FcRn Binding: Met252 Oxidation Impairs FcRn Binding More Profoundly than Met428 Oxidation
- (2015) Xuan Gao et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Association of Compounded Bevacizumab With Postinjection Endophthalmitis
- (2015) Brian L. VanderBeek et al. JAMA Ophthalmology
- Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection
- (2015) Nicolas A. Yannuzzi et al. JAMA Ophthalmology
- Quantification, Microbial Contamination, Physico-chemical Stability of Repackaged Bevacizumab Stored Under Different Conditions
- (2014) Leonarda Signorello et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies
- (2014) Jan Stracke et al. mAbs
- Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial
- (2013) Usha Chakravarthy et al. LANCET
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- META-ANALYSIS OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS
- (2011) Colin A Mccannel RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
- Qualitätsunterschiede zwischen Ranibizumab aus Originalbehältern und aus Fertigspritzen
- (2010) S. Grisanti et al. OPHTHALMOLOGE
- Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues
- (2008) Jan T. Andersen et al. FEBS Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started